CPT code 38212 describes the preparation of hematopoietic progenitor cell (HPC) products with maximal removal of red blood cells to reduce transplant complications, a critical step for marrow and cryopreserved cell transplants. Nationally, this procedure is central to safe hematopoietic stem cell transplantation programs and impacts clinical workflows, laboratory staffing, and facility billing practices. Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical and billing context for 38212, an overview of common payer coverage patterns and reimbursement considerations, and the clinical rationale for aggressive red cell depletion in HPC products. The publication also outlines typical sites of service and how this code fits into transplant episode billing. Data not available in the input is noted where applicable. This piece serves clinicians, transplant program administrators, and billing professionals seeking a national summary of the code's purpose, payer landscape, and implications for transplant laboratory operations.